Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan
Status:
Completed
Trial end date:
2017-08-02
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to investigate the relative Bioavailability (BA) of
tablet formulation of Dabigatran etexilate (DE) with and without co-administration of
rabeprazole in healthy male subjects.
The secondary objective is the evaluation and comparison of several pharmacokinetic
parameters between the treatments.